The pharmacokinetics of ceftazidime (CAZ) were studied in lactating (L
TG) and non-lactating (NLTG) cows. Two groups (LTG and NLTG) of 5 heal
thy dairy cows were given ceftazidime (10 mg/kg body weight) intraveno
usly (i.v.) and intramuscularly (i.m.). Serum and milk (LTG) and serum
samples (NLTG) were collected over a 24-h period post-administration
CAZ concentrations in serum and milk were determined by high-performan
ce liquid chromatography, and an interactive and weighted-non-linear l
east-squares regression analysis was used to perform the pharmacokinet
ic analysis. The pharmacokinetic profiles in LTG and NLTG cows which h
ad received CAZ i.v. fitted a three-compartment model and a two-compar
tment model, respectively. The CAZ concentration-time curves in serum
and the area under the curve were greater and more sustained (p <0.05)
in the LTG cows by both routes, while the serum clearance (Cl-s=72.5/-18.1 ml/h per kg) was lower (p <0.05) than that in the NLTG cows (Cl
-s=185.9+/-44.2 ml/h per kg). CAZ given i.v. exhibited a relatively lo
ng half-life of elimination (t(1/2 beta) (LTG)=1.1+/-0.2 h; t(1/2 beta
) (NLTG)=1.4+/-0.3 h). Compared with other on cephalosporins, CAZ had
good penetration into the mammary gland (47.7+/-38.2% for CAZ i.v.; 51
.1+/-1+/-39.0% for CAZ i.m.). Finally, the bioavailability of CAZ (F(L
TG)=98.9+/-36.8%;F(NLTG)=77.1+/-25.3%) was suitable for its use by the
i.m. route in lactating and non-lactating cows.